ICON (ICLR) Rebounds On A 90 Day Gain, Is It Still Trading At A Discount?
ICON (ICLR) drew fresh attention after recent trading left the stock at US$172.45, with short term moves contrasting with longer term returns that have been weaker over the past 3 years.
Recent trading has tilted in ICON's favor, with a 1-day share price return of 2.08% and a 7-day gain of 8.91% capping a 90-day share price return of 20.37%. This comes even as the year-to-date move is down 8.60% and the 3-year total shareholder return is down 34.49%, which points to short term momentum rebuilding after a tougher multi year stretch.
Scan beyond ICON and compare its recent swing in sentiment with 34 high quality undervalued stocks that also pair momentum with balance sheet strength.
Bulls see ICON's rebound and steady revenue and net income figures as support for a higher price. Bears focus on the weaker multi year return. Which case holds up once the valuation is on the table?
Most Popular Narrative: 7% Undervalued
ICON's most followed valuation view puts fair value at $185.56, modestly above the last close at $172.45, which keeps the focus squarely on whether earnings and margin expectations can support that gap.
ICON plans to continue significant share repurchases and evaluates M&A opportunities, underscoring their strategy to boost EPS and shareholder value. The company's balance sheet and disciplined capital deployment provide a foundation for potential growth through share repurchases and strategic acquisitions, aimed at increasing revenue and expanding market share in key areas like laboratory services.
See why 13 investors see ICON as 7% undervalued.
Result: Fair Value of $185.56 (UNDERVALUED)
Still, elevated clinical trial cancellations and pricing pressure across the contract research space could quickly challenge ICON's bookings momentum and the current undervalued narrative.
Find out about the key risks to this ICON narrative.
Next Steps
Mixed messages on ICON's outlook can pull you in either direction, so act while the debate is live and weigh the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond ICON?
If you stop at ICON, you risk missing companies that better match your goals. Put the Simply Wall Street Screener to work before the next move passes.
- Target potential mispricings by scanning a focused set of 34 high quality undervalued stocks that pair solid fundamentals with room for market expectations to catch up.
- Strengthen capital protection by filtering for 11 resilient stocks with low risk scores where balance sheets, earnings quality, and volatility profiles all point to reduced downside.
- Hunt for future standouts early by zeroing in on 16 high quality undiscovered gems that already show quality metrics before wider attention arrives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com